Akero Therapeutics, Inc. (AKRO)

Market Cap	3.19B
Revenue (ttm)	n/a
Net Income (ttm)	-269.44M
Shares Out	79.72M
EPS (ttm)	-3.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	979,477
Open	41.42
Previous Close	41.53
Day's Range	40.00 - 42.14
52-Week Range	17.86 - 58.40
Beta	-0.13
Analysts	Strong Buy
Price Target	76.00 (+89.95%)
Earnings Date	May 12, 2025

About AKRO

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: AKRO
• Website: https://akerotx.com

Analyst Forecast

According to 9 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $76.0, which is an increase of 89.95% from the latest price.

Price Target

$76.0

(89.95% upside)

Analyst Consensus: Strong Buy